# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-12 (automated)
**Previous report:** monitor_report_2026-07-11.md
**Scope:** Review of latest script outputs in `Analysis/Results/` + web breaking-news check

---

## Bottom line

Quiet day on the data side. The automated snapshot diff shows **zero** clinical-trial changes (no new trials, no status changes, no new results posted) vs. yesterday. PubMed rotated 37 in / 35 out with **2 new cross-domain papers**. All core data files are fresh (trials + PubMed regenerated today, gap analysis Jul 10–11). One genuinely new external item: **Kailera/Hengrui oral GLP-1 (HRS-7535) posted positive Phase 3 topline on Jul 7** — not yet in our trial set. Confidence on internal data: **[Certain]** (read from files). Confidence on "nothing material changed": **[Likely]** — limited by keyword-based diffing.

---

## File System Status

All expected pipeline files present and current:

| File | Last modified | Status |
|------|---------------|--------|
| clinical_trials_latest.json | 2026-07-12 02:04 | Fresh |
| clinical_trials_summary.md | 2026-07-12 02:04 | Fresh |
| pubmed_recent_latest.json | 2026-07-12 02:05 | Fresh |
| pubmed_recent_summary.md | 2026-07-12 02:05 | Fresh |
| hub_monitor_report.md | 2026-07-12 02:10 | Fresh |
| literature_gap_report.md | 2026-07-11 03:09 | Current (1 day) |
| literature_gap_data.json | 2026-07-10 02:17 | Current (2 days) |

Hub monitor tracked 1,036 files (3 new, 29 modified, 0 removed). The 3 new files are today's trial + PubMed snapshots and yesterday's monitor report — expected. Note the script's own flag: **810 result files >14 days old** — this is almost entirely the archive of dated snapshots and per-paper abstracts, not a pipeline problem. No action needed unless disk space is a concern.

---

## Clinical Trial Changes

**Day-over-day diff (snapshot 07-11 → 07-12): 0 new, 0 removed, 0 status changes, 0 new results.** Nothing changed in the tracked set of 855 trials.

Key Phase 3 programs being tracked (status unchanged):

| NCT | Sponsor | Therapy | Status |
|-----|---------|---------|--------|
| NCT04786262, NCT06832410 | Vertex | VX-880 / zimislecel (islet cell) | RECRUITING |
| NCT05791201 | Vertex | VX-264 (encapsulated islets) | ACTIVE, not recruiting |
| NCT07222137, NCT07222332 | Eli Lilly | Baricitinib (T1D beta-cell preservation) | RECRUITING |
| NCT07088068, NCT06791291, NCT07216391 | various | Teplizumab (delay/preserve) | RECRUITING / planned |
| NCT06972472, NCT06993792, NCT07668336, NCT07613307 | Eli Lilly | Orforglipron (oral GLP-1) | mix of active/planned |
| NCT05929079, NCT06297603, NCT06260722 | Eli Lilly | Retatrutide | ACTIVE, not recruiting |
| NCT06534411, NCT07564414, NCT07282613 | Novo Nordisk | CagriSema | mix of active/recruiting |

**Recently posted results worth a look** (already in-set, not day-over-day new):
- **NCT04255433** — Lilly tirzepatide vs. dulaglutide, results posted 2026-07-08.
- **NCT06340854** — Novo basal-insulin switch study, results posted 2026-07-02.
- **NCT06010004** — Lilly orforglipron long-term safety, results posted 2026-06-30.

106 trials in the set now carry 2026 results postings — a standing backlog for the "Clinical Trial Intelligence" Tier-1 area (cross-trial pattern analysis is the value-add the Doctrine calls for, and it isn't being done yet).

---

## PubMed Highlights

30-day lookback, 159 unique papers across 16 domains. Volume is flat/even (most domains capped at the 10-paper query limit), so no domain is anomalously hot or cold this cycle.

**New cross-domain papers since yesterday (highest priority — these are the 2 the diff flagged):**
- **[PMID 42435238]** *A machine learning approach to metabolomics identifies putative biomarker candidates* — **Diabetes AI/ML × Biomarker**. Directly on the Tier-1 Multi-Omics Biomarker Integration line.
- **[PMID 42436543]** *Dynamics of healthcare inequalities in type 2 diabetes across the COVID-19 pandemic* — **T2D Remission × Health Equity**.

**Other cross-domain papers in the current set (8):** T1D stem-cell × immunotherapy (42411999); teplizumab review (42332392); SGLT2/GLP-1 combo (42426564); calcium dysregulation in diabetic cardiomyopathy (42415984); microbiome × biomarker graph-learning (42429765); closed-loop × early retinopathy worsening (42420766); and two head-to-head incretin comparisons spanning orforglipron/retatrutide/CagriSema (42419792, 42394981).

**Key-therapy tracker:** all 8 tracked therapies (zimislecel, orforglipron, retatrutide, CagriSema, baricitinib, teplizumab, icodec, dapagliflozin) returned recent hits — no therapy went dark.

*Evidence note (per Doctrine): all PubMed items are abstract-level signals only — BRONZE until full-text and citation-verified.*

---

## Gap Analysis Summary

Top 5 under-researched intersections (from `literature_gap_data.json`, Gap Score 100 = zero or near-zero co-publication):

| Rank | Intersection | Joint pubs | Gap |
|------|--------------|-----------|-----|
| 1 | Beta Cell Regen × Health Equity | 0 | 100.0 |
| 2 | Insulin Resistance × Islet Transplant | 1 | 100.0 |
| 3 | Insulin Resistance × Closed Loop / AP | 3 | 100.0 |
| 4 | Islet Transplant × GWAS / Polygenic | 0 | 100.0 |
| 5 | Islet Transplant × Personalized Nutr | 0 | 100.0 |

**Alignment to Tier-1 contribution areas:** ranks 1 and 2 are actionable — they sit at the crossroads of our Literature-Synthesis and Drug-Repurposing/Multi-Omics Tier-1 lanes. Ranks 4 and 5 are flagged in the interpreted report as **methodologically distinct** (genomics vs. device/nutrition) — low overlap is expected structure, not a real opportunity. Treat those as deprioritized.

All gap classifications remain **BRONZE** (single analytical source; expert confirmation still pending — unchanged from prior runs).

---

## Breaking News (web check, last 7 days)

**Significant — new to our data:**
- **Kailera Therapeutics / Hengrui Pharma — HRS-7535 (KAI-7535), oral small-molecule GLP-1 RA.** Positive topline from **two China Phase 3 trials** (HARBOR-1 in obesity; OUTSTAND-2 in T2D), announced **2026-07-07**. Not currently in our tracked set — this is a non-Lilly/Novo oral GLP-1 program worth adding. [Likely significant]

**Noted but NOT new (already tracked, outside 7-day window — no action):**
- Tzield/teplizumab pediatric Stage-3 indication (FDA, 2026-06-12).
- First generic dapagliflozin (FDA, 2026-04-07).
- Retatrutide still pre-approval; NDA filing expected Q4 2026.

No FDA action in the trailing 7 days.

---

## Recommended Actions

1. **Add the Kailera/Hengrui HRS-7535 program to trial tracking.** It's an oral GLP-1 Phase 3 outside the current Lilly/Novo-centric set — a coverage gap. Search ClinicalTrials.gov for the HARBOR-1 / OUTSTAND-2 NCT IDs and fold them in on the next `baseline_clinical_trials.py` run.
2. **Review the 2 new cross-domain papers** — PMID 42435238 (AI/ML × Biomarker) maps straight onto Tier-1 Multi-Omics work; pull full text and citation-verify before any claim use.
3. **Refresh gap analysis** — `literature_gap_data.json` is 2 days old; fine for now, re-run `project1_literature_gap_analysis.py` within the week to keep it inside the 14-day freshness bar.
4. **No tracker edits required today** — zero trial changes means `Diabetes_Research_Tracker.xlsx` is still accurate for the trial set.
5. **Optional housekeeping:** the 810 stale-file flag is snapshot/abstract archive noise; consider a retention policy (e.g., keep weekly snapshots, prune dailies >30 days) if the folder count matters.

---

*Generated by diabetes-hub-monitor (automated review run). No existing files modified. All internal findings read directly from source files; external items web-verified 2026-07-12.*
